Standout Papers

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia 2016 2026 2019 2022 844
  1. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia (2016)
    Hagop M. Kantarjian, Daniel J. DeAngelo et al. New England Journal of Medicine

Immediate Impact

4 by Nobel laureates 17 from Science/Nature 55 standout
Sub-graph 1 of 22

Citing Papers

Natural killer cell therapies
2024 StandoutNature
Management of ALL in adults: 2024 ELN recommendations from a European expert panel
2024 Standout
1 intermediate paper

Works of Kongming Wang being referenced

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
2016 Standout

Author Peers

Author Last Decade Papers Cites
Kongming Wang 793 611 148 535 37 2.5k
D.A. Winfield 838 474 408 167 71 2.8k
Jan J. Heimans 752 1162 1236 311 63 3.8k
Jason E. Hill 697 953 191 83 50 3.3k
Félix Carbonell 263 1381 800 405 153 3.9k
James C. Lynch 619 2079 183 197 73 5.2k
Jeff Hall 804 405 198 162 47 4.3k
Ernst W. Radue 609 382 120 226 65 4.3k
Jan Lankelma 911 632 30 129 59 2.8k
Vasilios Κ. Kimiskidis 258 785 144 77 128 2.4k
A. Foss 461 187 73 334 131 4.0k

All Works

Loading papers...

Rankless by CCL
2026